CluePoints Survey Reveals that Determining the Best Approach is the Industry's Biggest Challenge to Implementing a Risk-Based Monitoring Strategy
A survey by CluePoints, a leading provider of Centralised Statistical Monitoring (CSM) solutions for clinical trials, has revealed that 42% of respondents from across the industry consider agreeing the best and most practical approach to be the biggest challenge their organisations are facing in implementing an effective Risk-Based Monitoring (RBM) strategy. While 2 years ago RBM was not at the top of many minds, today 36% of the 520 survey respondents are currently in the process of evaluating practices, calling for greater awareness of how sponsors and CROs can develop and integrate the approach at a realistic and practical level.
The new survey was developed to gain an understanding of the industry's insights into RBM and how changes to monitoring strategies are being managed at sponsor and CRO level. The research looked at the techniques that are currently available to the market with 59% of those surveyed pointing to the use of Central Statistical Monitoring as contributing major advantages from a usability perspective due to its ability to detect data accuracy and issues earlier, while requiring minimal work from study teams in gaining objective information.
"We carried out this survey to identify how people are managing making RBM a reality in their organisations and what is important to them at the moment. The survey findings have shown that the wealth of information that has been made available to the industry surrounding RBM over recent months has not armed decision makers with a clear understanding of how approaches can be practically implemented", comments Franҫois Torche, CEO of CluePoints. "Our CSM solutions have been developed to make implementing adaptive monitoring as straightforward as possible and simplify the transition for users. The new findings give insight into the needs of the industry and we are currently working with a wide range of sponsors and CROs to demonstrate how these new solutions can be pragmatically and straightforwardly included in their research designs."
Related News
-
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Pharma Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain. -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement. -
News BIOSECURE Act continues to loom over Chinese pharma manufacturers
With the US BIOSECURE Act on its way to passing into legislation, Chinese companies are facing declining revenues within the first half of 2024 as US pharmaceutical and healthcare companies pull their businesses from the country. -
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance